Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment (2024)
- Authors:
- Autor USP: SANTOS FILHO, RAUL DIAS DOS - FM
- Unidade: FM
- DOI: 10.1093/eurjpc/zwad332
- Subjects: COGNIÇÃO; HIPERCOLESTEROLEMIA; CRIANÇAS; ARTERIOSCLEROSE; SISTEMA NERVOSO CENTRAL
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: European journal of preventive cardiology
- ISSN: 2047-4873
- Volume/Número/Paginação/Ano: v. 31, n. 3, Special Issue, p. 302-310, 2024
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
SANTOS FILHO, Raul Dias dos et al. Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment. European journal of preventive cardiology, v. 31, n. 3, p. 302-310, 2024Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/58820. Acesso em: 20 fev. 2026. -
APA
Santos Filho, R. D. dos, Ruzza, A., Wang, B., Maruff, P., Schembri, A., Bhatia, A. K., et al. (2024). Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment. European journal of preventive cardiology, 31( 3), 302-310. doi:10.1093/eurjpc/zwad332 -
NLM
Santos Filho RD dos, Ruzza A, Wang B, Maruff P, Schembri A, Bhatia AK, Mach F, Bergeron J, Gaudet I, Pierre JS. Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment [Internet]. European journal of preventive cardiology. 2024 ; 31( 3): 302-310.[citado 2026 fev. 20 ] Available from: https://observatorio.fm.usp.br/handle/OPI/58820 -
Vancouver
Santos Filho RD dos, Ruzza A, Wang B, Maruff P, Schembri A, Bhatia AK, Mach F, Bergeron J, Gaudet I, Pierre JS. Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment [Internet]. European journal of preventive cardiology. 2024 ; 31( 3): 302-310.[citado 2026 fev. 20 ] Available from: https://observatorio.fm.usp.br/handle/OPI/58820 - Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension
- Familial hypercholesterolaemia: PCSK9 inhibitors are coming [comentário]
- Relation of Hepatic Steatosis to Atherogenic Dyslipidemia
- Cigarette smoking worsens systemic inflammation in persons with metabolic syndrome
- Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation
- USPSTF recommendation on screening for lipid disorders in children and adolescents. [Carta]
- Down the rabbit hole: reviewing the evidence for primary prevention of cardiovascular disease in people with obesity
- Relation Between Self-Reported Physical Activity Level, Fitness, and Cardiometabolic Risk
- Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know
- The Role of Statins in Current Guidelines
Informações sobre o DOI: 10.1093/eurjpc/zwad332 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
